Stock Movers: T-Mobile, MGM, Incyte (Podcast)

T-Mobile (TMUS) shares declined following news of Donald Trump's plan to launch a Trump-branded mobile phone service. Conversely, MGM (MGM) shares increased after BetMGM, its sports betting joint venture, raised its net revenue and EBITDA guidance for fiscal year 2025 due to strong second-quarter performance. Incyte (INCY) shares also rose after the company released clinical data from two trials of its experimental therapy for a blood disorder, which has garnered positive attention from Wall Street analysts.

Analysis

Market movements on June 16, 2025, were driven by distinct company-specific news. T-Mobile (TMUS) shares declined following the announcement of President Donald Trump's plan to launch a new Trump-branded mobile phone service, which aims to utilize "made in America" wireless networks and hardware, thereby introducing a new competitive dynamic to the telecom sector. Conversely, MGM Resorts International (MGM) experienced an increase in its share price after its sports betting joint venture, BetMGM, raised its net revenue and EBITDA guidance for fiscal year 2025, citing strong second-quarter trading performance and signaling continued momentum in the rapidly expanding sports betting market. In the biopharmaceutical space, Incyte (INCY) shares saw gains driven by the release of positive clinical data from two trials of its experimental therapy for a blood disorder, a development that has garnered favorable attention from Wall Street and suggests potential for a significant new product.

Key Decisions for Investors

• Investors in T-Mobile (TMUS) should closely monitor the development and market penetration of the new Trump-branded mobile service to assess the potential impact on T-Mobile's subscriber base and competitive positioning.
• The upward revision in BetMGM's guidance reinforces a positive outlook for MGM (MGM); investors should consider the continued growth trajectory of the sports betting segment as a significant value driver for the company.
• For Incyte (INCY), the positive clinical trial data presents a potential catalyst; investors should track the therapy's progress through regulatory approval stages, as successful commercialization could substantially enhance Incyte's revenue.